**In Vivo** Tracking and Comparison of the Therapeutic Effects of MSCs and HSCs for Liver Injury

Qiang Li*, Xinmin Zhou※, Yongquan Shi*, Jinge Li, Linhua Zheng, Lina Cui, Jun Zhang, Lu Wang, Zheyi Han, Ying Han*, Daiming Fan

State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi’an, Shaanxi Province, China

---

**Abstract**

*Background:* Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) have been studied for damaged liver repair; however, the conclusions drawn regarding their homing capacity to the injured liver are conflicting. Besides, the relative utility and synergistic effects of these two cell types on the injured liver remain unclear.

*Methodology/Principal Findings:* MSCs, HSCs and the combination of both cells were obtained from the bone marrow of male mice expressing enhanced green fluorescent protein (EGFP) and injected into the female mice with or without liver fibrosis. The distribution of the stem cells, survival rates, liver function, hepatocyte regeneration, growth factors and cytokines of the recipient mice were analyzed. We found that the liver content of the EGFP-donor cells was significantly higher in the MSCs group than in the HSCs or MSCs+HSCs group. The survival rate for the MSCs group was significantly higher than that of the HSCs or MSCs+HSCs group; all surpassed the control group. After MSC-transplantation, the injured livers were maximally restored, with less collagen than the controls. The fibrotic areas had decreased to a lesser extent in the mice transplanted with HSCs or MSCs+HSCs. Compared with mice in the HSCs group, the mice that received MSCs had better improved liver function. MSCs exhibited more remarkable paracrine effects and immunomodulatory properties on hepatic stellate cells and native hepatocytes in the treatment of the liver pathology. Synergistic actions of MSCs and HSCs were most likely not observed because the stem cells in liver were detected mostly as single cells, and single MSCs are insufficient to provide a beneficial niche for HSCs.

*Conclusions/Significance:* MSCs exhibited a greater homing capability for the injured liver and modulated fibrosis and inflammation more effectively than did HSCs. Synergistic effects of MSCs and HSCs were not observed in liver injury.

---

**Introduction**

Liver transplantation remains the definitive treatment option for end-stage liver disease. But the mismatch between the number of patients requiring transplantation and the amount of available organs is set to grow, highlighting the need to develop new strategies to reduce liver scarring and stimulate liver regeneration. Stem cell replacement strategies are therefore being investigated as an attractive alternative approach to liver repair.

To date, there are several published human clinical studies investigating the effects of stem cell therapy in patients with liver disease and most of the studies yielded positive results. The cells mostly used to transplant were derived from bone marrow including MSCs [1], HSCs [2,3] and unsorted mononuclear cells [4]. Among them, MSCs and HSCs can be obtained in a great quantity. MSCs represent excellent candidates for the following reasons: MSCs (i) can contribute to the direct production of new hepatocytes [4,5,6], (ii) can promote tissue repair by secreting trophic molecules [6,7,8], (iii) are immunomodulatory and hypoinmunogenic (i.e., in addition to not being recognized by the recipient’s immune system unlike allogeneic transplants, MSCs could manage exacerbated inflammatory process) [9,10,11] and (iv) have anti-fibrotic properties and inhibit the activation of hepatic stellate cells [11,12]. HSCs represent another significant stem cell type in bone marrow. The liver-specific phenotypic and functional changes of a highly enriched population of HSCs in response to injury in vitro or in vivo have been examined. HSCs also have many of the following advantages: HSCs (i) can also be converted into functional hepatocytes without fusion and therefore contribute to the regeneration of injured liver [13], (ii) can reduce liver injury through paracrine effects [4] and (iii) can modulate the immune system of the recipient [14]. However, which cell type is more effective in treating the injured liver remains to be determined. Moreover, several recent studies have suggested that MSCs and HSCs function synergistically for the therapy of diabetes and heart failure and for vascularizing bioengineered tissues [15,16,17]. Whether these cells can work synergistically in the injured liver is unclear.
Our aim was to evaluate the biodistribution of the stem cells after the peripheral infusion of MSCs or HSCs into liver injured mice. The anti-inflammatory and anti-fibrotic activities of these two stem cells were also evaluated. In addition, whether MSCs and HSCs exhibit synergistic effects in treating liver injury was studied. We hope that these findings contribute to better understanding of the interactions between stem cells and the environment that leads to homing and integration into livers.

**Materials and Methods**

**Mice**

Breeding pairs of C57BL/6-Ly5.1 mice and EGFP transgenic mice (C57BL/6-Ly5.2 background) were purchased from the animal center of the Fourth Military Medical University. All aspects of the animal research were approved by the Animal Care and Use Committee of the Fourth Military Medical University (Approval ID 12008) and were in compliance with Guidelines for the Care and Use of Laboratory Animals, as published by the National Academy Press.

**Isolation and Characterization of HSCs**

Male EGFP transgenic mice 9 to 12 weeks old (19 to 24 grams) were used as bone marrow donors. The mice were humanely sacrificed and the bone marrow cells were flushed from the tibiae and femurs, pooled, and washed twice with Ca²⁺/Mg²⁺-free phosphate-buffered saline (PBS; Beyotime, China) containing 0.1% bovine serum albumin (BSA) (Beyotime, China). Single-cell suspensions were produced after repeated pipetting and filtering through a 50-μm nylon mesh. Bone marrow cells with densities ranging from 1.063 to 1.077 g/ml were collected by gradient separation using Nycodenz (Sigma, USA). Lineage negative (Lin⁻) bone marrow cells of the EGFP-expressing mice were prepared by incubating the cells with anti-macrophage-1 (Mac-1), anti-granulocyte receptor-1 (Gr-1), anti-TER-119, anti-B220, anti-CD4 and anti-CD8 and then by removing the positive cells with immunomagnetic beads (Dynabeads M-450 coupled to sheep anti-rat IgG) (Dynal, Great Neck). The resulting Lin⁻ cells were stained with phycoerythrin (PE)-conjugated anti-Sca-1, biotin-conjugated anti-CD34, and APC-conjugated anti-c-kit and with the mouse lineage panel of antibodies, followed by streptavidin-conjugated PharRed. After the addition of propidium iodide at a concentration of 1 μg/ml, the cells were washed twice, resuspended in PBS containing 0.1% BSA, and maintained on ice for cell sorting. Five-color and cell sorting analyses were performed using a FACSort Vantage (BD Biosciences, San Jose) with the appropriate isotype-matched controls. The Lin⁻ cells were enriched for the c-kit⁺/Sca-1⁺ population. Single Lin⁻, c-kit⁺, Sca-1⁺, CD34⁻ cells were deposited into round-bottomed 96-well plates using the CloneCyt system (Becton Dickinson, USA). The plates were incubated at 37°C in a humidified 5% CO₂ atmosphere. At 20 hours after cell deposition, the wells containing single cells were marked and incubated for 7 days. We selected clones consisting of no more than 20 cells for clonal cell transplantation [10].

**Isolation, Expansion, and Phenotypic Characterization of MSCs**

Bone marrow cells were collected after flushing the tibiae and femurs of 6-week-old male EGFP-expressing mice (14 to 17 grams) using sterile PBS. The cells were aspirated with a 29-gauge needle to disrupt aggregates, and then the entire aspirate was centrifuged at 2,000 rpm for 10 min. The pellet was seeded into a 25-cm² culture plate with alpha-MEM (Gibco, USA) medium supplemented with 10% selected fetal bovine serum (FBS; Gibco, USA), an anti-mycotic solution (Sigma, USA) and 1% antibiotics. The non-adherent cells were removed after 72 h by changing the medium, and the medium was entirely replaced every 3 days [19]. When the foci reached confluence, the adherent cells were detached with 0.25% trypsin in 2.65 mM EDTA (Sigma, USA), centrifuged, and subcultured at 7,000 cells/cm². After two subcultures, the adherent cells were detached, and the cells were stained with PE-conjugated antibodies against CD29, CD90, CD34, CD105, CD80 and CD45 (Santa Cruz, USA) antigens for 30 min and then washed and analyzed using a flow cytometer (BD Biosciences, USA).

![Figure 1. Characterization of MSCs derived from EGFP-transgenic mice.](image-url)

(A) The morphologies of the MSCs in the first (i and ii) and third (iii and iv) passages observed under bright field and fluorescence microscopy, respectively. (B) Surface molecule characterization of the MSCs performed by FACS analyses after incubation with PE-conjugated antibodies (CD90, CD29, CD105, CD45, CD34 and CD80). doi:10.1371/journal.pone.0062363.g001
Detection of EGFP+ cells in recipient livers after transplantation. EGFP+ cells from male donors were injected into liver-injured female mice. (A) After transplantation of stem cells, the EGFP fluorescence in the lung, liver, spleen and kidney was examined using bio-imaging system. A luminescent image from red (least intense) to yellow (most intense) represents the spatial distribution of the detected photons emitted.
from EGFP+ cells within the organs. The EGFP signal was not detected in the control mice. (B) Average radiance was quantified in the liver after stem cells transplantation. (C) PCR-based detection of donor-derived cells in the livers of different recipients. (D and E) Liver sections were stained with DAPI, and the distribution of EGFP+ cells in the portal lobe was quantified in the different groups at 4 weeks. White arrows show the stem cells in the sinusoids (i, MSCs group; ii, HSCs group; and iii, MSCs+HSCs group). (F and G) FACS analyses of CXCR4 expression on MSCs and HSCs. (H) mRNA levels of CXCR4 on MSCs and HSCs. P<0.05, n = 3.

doi:10.1371/journal.pone.0062363.g002

Induction of Liver-injured Mice

Wild-type mice (9 to 12 weeks old, 19 to 24 grams) were housed in a sterile animal facility with a 12-hour dark/light cycle and free access to food and water. Advanced liver fibrosis was induced in adult female mice with intraperitoneal injections of 7 ml/kg body weight of a 1:4 solution of CCl4 (Sigma, USA) and olive oil (Sigma, USA) twice a week for 3 months [18]. After final CCl4 injection at 3 months, the mice except the control group were randomly divided into different groups to ensure that the relatively level of liver disfunction was constant. Mice from the same cohort were randomly allocated to receive different cell stem cells via injections of the tail vein. The candidate stem cells from age- and strain-matched mice were suspended in 0.1 ml of PBS. CCl4 administration continued for an additional four weeks.

Cell Transplantation

A total of 1×10⁶ cells were resuspended in 100 μL PBS and slowly infused via the tail vein (Normal, MSCs, HSCs and MSCs+HSCs treatment groups). Following transplantation, CCl4 was re-administered for four additional weeks (7 ml/kg body weight of a 1:4 solution of CCl4 and olive oil twice a week) to enable the transplanted cells to engraft and differentiate. CCl4 was not administered to the normal group (n = 20) during this period. In the CCl4 group (n = 22), the mice were injected with CCl4 alone, without cell transplantation. In the MSCs group (n = 22), the mice were administered MSCs. In the HSCs group (n = 22), the mice were administered HSCs. In the MSCs+HSCs group (n = 22), the mice were administered 5×10⁵ MSCs and 5×10⁵ HSCs [17].

Bio-imaging

The mice were sacrificed under deep anesthesia at 2 h, 24 h, 7 d and 28 d after transplantation. The lungs, livers, spleens and kidneys were isolated and were directly imaged by CCD with its excitation wavelength at 465/430 nm and emission filter at 560 nm with the following parameters: binning: 4, F/Stop: 1, exposure time: 1 min. The bio-imaging was conducted with a NightOWL imaging system using WinLight software (Berthold, Germany).

Tissue Preparation and Confocal Microscopy

To observe the engrafted cells in the liver, the tissues were prepared as frozen sections. The livers were dissected into pieces, immediately incubated with an optimal cutting temperature compound (OCT compound, Sakura Fine technical, Japan) and held in liquid nitrogen for 20 seconds. The frozen liver sections were directly transferred to a –270°C freezer. For observing the EGFP-expressing cells in the tissue, the frozen sections were allowed to melt in distilled water for 3 min and placed on slides.

Polymerase Chain Reaction

Genomic DNA was isolated from each liver using a lysis buffer containing 1% of 0.2 mg/ml protease K (Sigma, USA) and SDS followed by phenol-chloroform extraction. The genomic DNA was used to detect a Y chromosome sequence with the forward primer CTGGAGCTCTACAGTGATGA and the reverse primer CAGTTACCAATCAACACATCAC. The PCR products were

Figure 3. Therapeutic effects of transplanted MSCs, HSCs and MSCs+HSCs on recovery in the CCl4-induced injury mouse model. (A) A survival curve for the injured mice that underwent intravenous cell transplantation. Representative photomicrographs of H&E-stained (B) and Sirius red-stained (C) mouse livers from the different groups (i, normal mice; ii, CCl4 group; iii, MSCs group; iv, HSCs group; and v, MSCs+HSCs group). (D) Analyses of the fibrosis percentage using Image J software. (E) mRNA levels of type I collagen. (F, G and H) Serum ALB, ALT and AST levels in the experimental groups. P<0.05, n = 5, Scale bars: B = 150 μm, C = 200 μm.

doi:10.1371/journal.pone.0062363.g003
Figure 4. Effect of MSC, HSC and MSC+HSC transplantation on hepatocyte regeneration. (A) Immunohistochemistry analyses of PCNA expression in liver tissues (i, normal mice; ii, CCl4 group; iii, MSCs group; iv, HSCs group; and v, MSCs+HSCs group). (B) Immunohistochemistry analyses of Ki-67 expression in liver tissues (i, normal mice; ii, CCl4 group; iii, MSCs group; iv, HSCs group; and v, MSCs+HSCs group). (C) Quantitative image analyses of the percentage of Ki-67+ cells. (D) Quantitative image analyses of the percentage of PCNA+ cells. P<0.05, n = 5, Scale bar = 100 μm.
Figure 5. Differentiation of transplanted MSCs, HSCs and MSCs+HSCs in CCl4-induced injured livers at 4 weeks. The liver sections were observed under fluorescence microscopy. (A, B and C) The liver sections were co-stained with either AFP or ALB to detect the differentiation of transplanted cells (white arrowhead) in the different groups. (D) The expression of α-SMA in the livers of CCl4-induced injured mice in the different groups (i, normal mice; ii, CCl4 group; iii, MSCs group; iv, HSCs group; and v, MSCs+HSCs group). (E) mRNA levels of α-SMA. *P<0.05, n = 5, Scale bars: A = 50 μm, D = 150 μm. doi:10.1371/journal.pone.0062363.g005
fractionated by 1.2% agarose gel electrophoresis and visualized under UV illumination after staining with ethidium bromide.

Biochemical and Liver Enzyme Assays

Serum was collected to analyze aspartate aminotransferase (AST), alanine aminotransferase (ALT), and albumin (ALB) using a chemistry analyzer (Abbott Architect c8000, USA).

Histopathological Staining

For the histological examinations, formalin-fixed livers were dehydrated and embedded in paraffin. The liver sections were deparaffinized and stained using hematoxylin and the eosin stain or Sirius red. For immunohistochemical studies, after microwave-based antigen retrieval, the sections were treated with 0.3% H<sub>2</sub>O<sub>2</sub> in PBS to quench the endogenous peroxidase and then incubated with 5% goat serum (Beyotime, China) to block the non-specific sites. Monoclonal primary antibodies against mouse Ki-67 (1:100, Abcam, USA) were applied when incubating at 4°C for 12 h, followed by incubation with the corresponding secondary antibodies (Beyotime, China) at 37°C for 30 min. The specimens were then incubated with a diaminobenzidine peroxidase substrate and then subsequently counterstained with hematoxylin. For the immunofluorescence analyses, the tissue samples were fixed using 4% paraformaldehyde (Beyotime, China) and then permeabilized using 0.1% Triton X-100. The samples were blocked using 5% BSA and then incubated overnight at 4°C with alpha-fetoprotein (AFP) (1:200, Abcam, USA), ALB (1:200, Abcam, USA), proliferating cell nuclear antigen (PCNA) (1:500, Abcam, USA), and alpha-smooth muscle actin (α-SMA) (1:500, Abcam, USA) antibodies diluted in antibody dilution solutions (Beyotime, China). The excess primary antibody was removed by washing five times in PBS, and the samples were incubated with a PE-conjugated secondary antibody (1:500) at room temperature for 2 hours. The sections were incubated with 4′, 6-diamidino-2-phenylindole (DAPI; Beyotime, China) to label the nuclei. The slides were mounted in propidium iodide-containing mounting medium (Beyotime, China) for visualization using a confocal microscope (FV-1000, Olympus, Japan).

Fluorescence-Activated Cell Sorting (FACS)

The MSCs and HSCs suspension was incubated with PE-labeled anti-mouse CXCR4 antibody (1:500, BD Pharmingen, USA) on ice for 1 h, washed with staining buffer, and fixed with 2% paraformaldehyde. FACS data were acquired using a flow cytometer (BD Biosciences, USA) [20]. Data were analyzed using CellQuest software.

Real-time PCR

Total RNA was isolated from fresh liver tissue and stem cells using Trizol reagent (Life Technologies, USA), and the ratio between the absorbance values at 260 and 280 nm provided an estimate of the RNA purity. Real-time PCR was performed using a one-step kit (Takara, Japan) with the following primers: α-SMA: forward: GGGAGTAATGGTTGGAATGG, reverse: GGCAG-

Figure 6. The concentration of growth factors and cytokines in each group 4 w after transplantation of MSCs, HSCs or MSCs+HSCs.

P<0.05, n = 5. NGF, nerve growth factor; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; IL, interleukin; TNF-α, tumor necrosis factor-alpha.

doi:10.1371/journal.pone.0062363.g006
MSCs were also successfully isolated for use in the following results. The percentage of EGFP-positive cells for the normal group (Fig. S1). The donor-derived signals were stronger induced cirrhotic liver was significantly higher than that in the normal group. EGFP signal intensity gradually increased in the spleen and then intensity gradually increased in the liver. From 24 h to 7 d, the infusion. During the following hours to days, the EGFP signal was barely detectable in the kidney. EGFP signal intensity gradually increased in the liver. From 24 h to 7 d, the

**Characterization of EGFP-positive MSCs**

Enzyme-linked Immunosorbant Assays

Quantification of the mouse serum levels of nerve growth factor (NGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), IL-10, IL-6 and tumor necrosis factor-alpha (TNF-α) was determined using enzyme-linked immunosorbent assays kits per the manufacturer’s instructions (R&D Systems, USA), and the wells were read at 450 nm on an optical plate reader. Standard curves were prepared using purified cytokine standards. Each experimental sample was run in duplicate.

Data Analyses

The data are expressed as the mean with the standard error of the mean. The statistical significances were determined using SPSS 12.0 software (SPSS, USA). The statistical significances between the control and test groups were determined using Student’s t-test. For the analyses of multiple groups, the P-values were adjusted using the Bonferroni method and a P<0.05 was used for statistical significance. All of the procedures were performed by blinded investigators.

**Results**

Characterization of EGFP-positive MSCs

The MSCs were isolated from the bone marrow of EGFP-transgenic mice. In the first passage, the cells derived from the donors emitted homogeneous levels of green fluorescence when observed under the fluorescence microscope and were of various sizes, as observed in bright field. In the third passage, the EGFP signal intensity was uniform among the cells, and the cells exhibited a homogeneous morphology (Fig. 1A). Flow cytometry analyses were used to characterize the surface markers of the cultured cells. Most of the cells expressed the standard MSC surface markers, CD90 (95.2 ± 6.1%), CD29 (85.6 ± 3.5%) and CD105 (96.5 ± 4.3%), whereas they were negative for CD45 (6.3 ± 2.2%), CD34 (7.2 ± 1.8%) and CD80 (3.8 ± 1.2%) (Fig. 1B). MSCs were also successfully isolated for use in the following experiments.

**Detection of Donor-derived Cells**

After intravenous infusion, the EGFP signals first accumulated in the lung, but by 2 h, those signals began to decrease, whereas they started to accumulate in the liver and spleen at 2 h after infusion. During the following hours to days, the EGFP signal intensity gradually increased in the liver. From 24 h to 7 d, the EGFP signal intensity gradually increased in the spleen and then decreased. The EGFP signal was barely detectable in the kidney. These trends were similar in the MSCs, HSCs and MSCs+HSCs groups (Fig. 2A). The EGFP intensity of the livers in the MSCs group was significantly higher than in the HSCs or MSCs+HSCs group (Fig. 2B). The number of homing stem cells to the CCl4 was significantly lower than in the other two groups. The EGFP signal intensity was uniform among the cells, and the cells showed maximal restoration with thinner fibrotic areas and decreased collagen depositions (3.6 ± 0.7%). However, the fibrotic areas had decreased to a lesser extent in the mice transplanted with HSCs (7.6 ± 0.8%) or MSCs+HSCs (6.2 ± 1.7%, P<0.05) (Fig. 3D). These results were confirmed by the expression of type I collagen (4.0 ± 1.1%, 6.3 ± 3.1%, 5.7 ± 1.5%, respectively, P<0.05) (Fig. 3E). Moreover, when compared with the mice in the HSCs group, the HSCs+MSCs group showed the best improvement of liver function, however, liver function in MSCs group was still inferior than in the normal group, as demonstrated by the ALB, ALT and AST levels of the peripheral blood (Figs. 3F, 5G and 3H). To evaluate whether stem cell transplantation enhances the proliferation of hepatocytes in cirrhotic livers, the PCNA and Ki-67 expression levels were assessed by immunofluorescence and immunohistochemistry. In the MSCs-transplanted livers, the percentage of PCNA + (11.5 ± 3.4%) and Ki-67 + (8.2 ± 2.7%) cells was increased significantly when compared with those of the HSCs (6.9 ± 1.8%, 6.0 ± 1.1%, respectively) and MSCs+HSCs (5.5 ± 3.1%, 7.2 ± 1.9%, respectively, P<0.05) groups (Figs. 4A, 4B, 4C and 4D).

**Derivation of Transplanted Cells**

The immunofluorescence staining in the HSCs group revealed a higher percentage of double-labeled GFP+/AFP+ and GFP+/ ALB+ cells in the host livers (4.3 ± 0.6% and 3.5 ± 0.7%, respectively), compared with the MSCs (1.4 ± 0.5% and 2.1 ± 0.3%, respectively) or the MSCs+HSCs (2.8 ± 0.4% and 2.4 ± 0.6%, respectively, P<0.05) groups (Figs. 5A, 5B and 5C). The expression of α-SMA was significantly decreased in the livers of mice transplanted with any cell type. The α-SMA expression in the MSCs group was significantly lower than in the other two groups (Figs. 5D and 5E). Double-labeled GFP+/α-SMA+ cells were not found in any of the groups.
Growth Factor and Cytokine Levels in Each Group

Four weeks after cell transplantation, the serum showed a significant increase in NGF in the MSCs (101±12 pg/ml) group when compared with the HSCs and MSCs+HSCs groups (53±5 pg/ml and 69±7 pg/ml, respectively, P<0.05). The levels of HGF and VEGF were not significantly different among the cell transplantation groups. The expression of IL-10 in the MSCs group (98±22 pg/ml) was higher than in the other cell transplantation groups (HSCs and MSCs+HSCs groups: 42±14 pg/ml and 66±21 pg/ml, respectively) or the CCl4 group (21±4 pg/ml, P<0.05), whereas the concentration of IL-6 (45±15 pg/ml) and TNF-α (140±75 pg/ml) in the MSCs group was lower than that of HSCs (IL-6:17±13 pg/ml, TNF-α: 227±87 pg/ml) and MSCs+HSCs (IL-6:60±9 pg/ml, TNF-α: 183±15 pg/ml, P<0.05) groups (Fig. 6).

Discussion

In this study, we conducted a comparison of MSCs and HSCs in vivo engraftment capaisties, as well as the administration of MSCs, HSCs and MSCs+HSCs for functional liver repair using the same liver fibrosis mouse model. The major findings of our study were the following: (i) when compared with HSCs alone and a combination of HSCs and MSCs, MSCs had the greatest homing capability to the injured liver; (ii) MSCs showed the greatest capability to promote hepatocyte proliferation, inhibit hepatic stellate cell activation in vivo and facilitate mice survival when compared with other two groups; and (iii) synergistic effects of MSCs and HSCs were not observed in CCl4-induced liver injury.

Cell homing and engraftment into the host liver are integral to cell-based therapies. The mechanism that governs the recruitment of bone marrow stem cells is complicated. Several signaling pathways [21,22,23] and growth factors [24] have been shown to contribute to the recruitment of bone marrow cells to the injured organs. Stress in the liver results in the release of various chemokines/cytokines including stromal-derived factor-1 (SDF-1) and HGF. These increase stem cells mobility through the cell surface receptors [e.g. chemokine receptor-4 (CXCR4) and hepatocyte growth factor receptor (c-met)], facilitating stem cells homing to sites of wound healing [25,26,27]. SDF-1-CXCR4 and HGF-c-met axes may be involved in recruitment of expanded MSCs to damaged tissues while only SDF-1-CXCR4 axes is involved in stress-induced HSCs recruitment to the injured liver [26,27].

Previous studies regarding the homing capacity of stem cells to the injured liver have reported conflicting conclusions. Some reported that the stem cells gradually accumulated in the liver [25,28]; however, one study demonstrated that the transplanted MSCs reached a peak amount in the liver 1 day after perfusion, and then the MSCs content gradually declined [29]. A few of the studies provided information concerning the biodistribution of the cells in major organs or compared the homing capacities of MSCs and HSCs to the injured liver.

To overcome these limitations, for the present investigation, highly purified and functionally active EGFP+ MSCs and HSCs isolated from bone marrow were transplanted intravenously into mice with CCl4-induced chronic liver injury. Our data showed that the EGFP signals were detected not only in livers but also in other tissues, such as the lungs and spleens. The distributions of these two stem cells were similar and both migrated effectively to the liver rather than to the lung, spleen and kidney in mice with CCl4-induced liver injury. The MSCs and HSCs gradually accumulated in the liver after they were first observed there.

Furthermore, we found that MSCs exhibited a more superior homing ability to the injured liver in comparison with HSCs, which would help them exert their effects there. Meanwhile, fluorescence-activated cell sorting and Real-time PCR analyses of CXCR4 expression on both stem cells revealed that CXCR4 expression in MSCs in the third passage was higher than in HSCs.

As for the localization of stem cells in the liver, Sakaida et al. transplanted bone marrow cells into mice with liver fibrosis and found that the cells predominantly engrafted to the portal area [30]. Additionally, di Bonzo et al. determined the location of human MSCs that were transplanted into mice and reported that the human cells were detected mostly around the portal tracts in injured livers [31]. Our results showed that in both injured and non-injured livers, the stem cells were detected mainly as single cells around the portal tracts and in the interlobular connective tissue. The stem cells were also detected in the sinusoids. This finding is most likely the result of the space of Disse being composed of sinusoidal endothelial cells and these cells being able to release SDF-1 [32] and SDF-1can attract stem cells.

The transdifferentiation ability of bone marrow-derived stem cells into hepatocytes may play a significant role in the repair of the injured liver [13,33,34]. AFP and ALB typically expressed in stem cells-derived hepatocytes [25,35,36]. However, our data showed that at 4 weeks after transplantation, the standard time of most research studies [31], the number of EGFP+ cells with a hepatocyte phenotype was relatively low, and the apparent number of HSCs in this model was slightly higher than that of MSCs. These cells were limited to a small portion of the total liver mass and were not sufficient to reverse the injuries (a percentage of 2.5–5% is necessary for this process [37]). Therefore, the differentiation of these two stem cells into hepatocytes cannot explain the improvement of liver function in this study.

The concept of stem cell transplantation exerting a paracrine proliferative effect on endogenous hepatocytes is gaining support. Hepatocytes in fibrotic livers have reached replicative senescence after many rounds of injury and repair, and they have reduced proliferative capacity [38,39,40,41]. Stem cell infusion may increase the intrinsic ability of hepatocytes to proliferate by facilitating the breakdown of scar tissue or by the release of proliferative cytokines, thereby removing a block to proliferation [20]. Diarmuid et al. concluded that HSCs might reduce the liver injury through paracrine effects. The expression of growth factors, including HGF and VEGF, promote liver regeneration and hepatocyte proliferation [4,42]. In addition to their differentiation to hepatocytes, MSCs infusions can also exert a paracrine proliferative effect on endogenous hepatocytes. The primary cytokines include HGF, VEGF, and NGF, which are reported to increase the intrinsic ability of hepatocytes to proliferate or to facilitate the breakdown of scar tissue [20,43,44,45]. In this study, the expression levels of NGF in the MSCs group were higher than in the HSCs group, while the levels of HGF and VEGF were not significantly different in each group. We also discovered more significant hepatocyte proliferation in the MSCs group relative to the other groups. Therefore, the improvement of liver functions by MSC transplantation was partially contributed to enhancing hepatocyte proliferation.

Furthermore, the immunomodulatory properties of MSCs and HSCs can also play a significant role in the extenuation of liver injury. The local down regulation of pro-inflammatory cytokines and up regulation of anti-inflammatory cytokines, such as IL-10, after MSC transplantation has been described in kidney, lung injury and fulminant hepatic failure models [46,47]. Pulavendran et al. found that IL-6 and TNF-α, which can be down regulated by IL-10 and are promoters of liver fibrosis, were lower in the...
MSCs group when compared with the control group in acute CCl4-induced liver injury. These authors also reported that HSCs did not seem to have any role in immunosuppression, and hence, its therapeutic application in the case of liver fibrogenic diseases is doubtful [48]. While Li et al. reported that autologous HSCs transplantation increased positively correlated with the concentrations of serum IL-10 but negatively correlated with the levels of serum TNF-α in patients with type 1 diabetes [14]. Whether HSCs exhibit immunomodulatory properties in chronic CCl4-induced liver cirrhosis remains unclear. Our data show that the concentration of IL-10 was higher in MScs group than in the HScs group, although the levels in both groups were higher than that in the control group. However, the concentrations of IL-6 and TNF-α in the MScs group were lower than those in the HScs group. Because the proinflammatory phase followed by the injury leads to the induction of fibrosis, opposing the proinflammatory cytokines results in the reversal of hepatic fibrosis. Thus, anti-inflammatory cytokines can reduce liver injury and then reduce hepatic fibrosis.

Several studies have demonstrated the synergistic actions of HScs and MScs in tissue regeneration and engineering. Moioli et al. found that the co-transplantation of HScs and MScs facilitated the neovascularization process in the bioengineered bone [15]. Consistently, these phenomena were also found in heart failure patients treated with a combination of HScs and MScs [17]. The rationale for combining these two stem cell populations came from several perspectives that include: i) both MScs and HScs are mobilized after tissue injury, and thus, potentially administering both cell types may produce therapeutic synergistic activity in the injured tissue [49,50,51]; ii) in vitro, MScs promote the expansion of HScs; in vivo, MScs provide a microenvironment for HScs in both the embryonic and postnatal stage [52]. In this study, however, the synergistic actions of MScs and HScs had not been observed because the stem cells in liver were detected mostly as single cell which are insufficient to provide a beneficial niche for regulating the self-renewing and differentiation of HScs.

In conclusion, these results suggest that MScs have a greater ability to modulate chemically induced inflammation in the fibrotic liver than do HScs. However, liver fibrosis has different causes, including alcoholic hepatitis, allograft rejection, autoimmune hepatitis and metabolic diseases. All of these disease mechanisms are quite different. In addition, the different stem cells have a variety of putative functional roles; thus, careful thought is required as to what biological action is intended from their infusion. Accordingly, further studies are needed concerning the choice of a cell therapy for specific types of liver injury.

**Supporting Information**

Figure S1 Comparison of recruitment of stem cells to the CCl4-induced cirrhotic liver and the normal liver. The average radiance was quantified in the liver after stem cells transplantation. (A)MScs group; (B) HScs group; and (C) MScs+HScs group. *P*<0.05, n = 3. (TIF)

**Author Contributions**

Conceived and designed the experiments: QL, XMZ, YQS, YH. Performed the experiments: QL, JGL, LNC, LHZ, LW. Analyzed the data: ZYH, YQS, JZ, YH. Contributed reagents/materials/analysis tools: XMZ, JGL, YH. Wrote the paper: QL, YQS, YH.

**References**

1. Peng L, Xie DY, Liu BL, Liu J, Zhu HP, et al. (2011) Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 54: 820–828.
2. Yannaki E, Anagnostopoulos A, Kapetanou D, Xagorari A, Iordanidis F, et al. (2006) Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol 34: 1583–1587.
3. am Esch JS 2nd, Knoefel WT, Klein M, Ghodsiadz A, Fuerst G, et al. (2005) Portal application of autologous CD34+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 23: 463–470.
4. Houlihan DD, Newsome PN (2008) Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 135: 438–450.
5. Zhao Q, Ren H, Zhu D, Han Z (2009) Stem/progenitor cell therapy in liver injury repair and regeneration. Biol Cell 101: 557–571.
6. Fang B, Shi M, Liao L, Yang S, Liu Y, et al. (2004) Systemic infusion of FLK1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 78: 83–88.
7. Zhao W, Li JJ, Gao DY, Li X, Zhang LY, et al. (2012) Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 18: 1048–1058.
8. van Poll D, Parekkadan B, Cho GH, Berthiaume F, Nahmias Y, et al. (2008) Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634–1643.
9. Shi Y, Hu G, Su J, Li W, Chen Q, et al. (2010) Mesenchymal stem cell: a new model for studying mesenchymal stem cells in vivo. Hepatology 52: 1069–1077.
10. Rasmussen I (2006) Immunomodulation by mesenchymal stem cells. Exp Cell Res 312: 2169–2179.
11. Parekkadan B, van Poll D, Margreid Z, Kobayashi N, Tilles AW, et al. (2007) Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun 355: 267–272.
12. Zhao DC, Lei JX, Chen R, Yu WH, Zhang XM, et al. (2005) Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 11: 3424–3430.
13. Jiang YY, Collector MI, Baylin SB, Dief H, Markin SJ (2004) Hepatopietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 6: 532–539.
14. Li L, Shen S, Ouyang J, Hu Y, Hu L, et al. (2012) Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 97: 1729–1736.
15. Moioli EK, Clark PA, Chen M, Dennis JE, Erickson HP, et al. (2008) Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. PLoS One 3: e3922.
16. Urban VS, Kisu J, Kovacs J, Gioca E, Vas V, et al. (2008) Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26: 244–253.
17. Ichim TE, Solano F, Lara F, Rodriguez JP, Cristina O, et al. (2010) Combination stem cell therapy for heart failure. Int Arch Med 3: 5.
18. Miyata E, Masuya M, Yoshida S, Nakamura S, Kato K, et al. (2008) Hematopoietic origin of hepatic stellate cells in the adult liver. Blood 111: 2427–2435.
19. Enquer M, Enquer F, Ricca M, Alers C, Conget P (2011) Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. J Hepatol 55: 1112–1120.
20. Wang J, Zhou X, Cui L, Yan L, Long J, et al. (2010) The significance of CD14+ monocytes in peripheral blood stem cells for the treatment of rat liver cirrhosis. Cytotherapy 12: 1022–1034.
21. Belema-Bedada F, Uchida S, Martin A, Kostin S, Braun T (2008) Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2: 566–575.
22. Li G, Gong Y, Wang H, Wang S, Yu H, et al. (2009) Homing of bone marrow mesenchymal stem cells mediated by spondine-1 contributes to liver fibrosis. J Hepatol 50: 1174–1183.
23. Meudt M, Cardier JR (2012) Stromal-derived factor-1 and its receptor, CXCR4, are constitutively expressed by mouse liver sinusoidal endothelial cells: implications for the regulation of hematopoietic cell migration to the liver during extramedullary hematopoiesis. Stem Cells Dev 21: 2142–2151.
24. Kawai K, Xue F, Takahara T, Kudo H, Yata Y, et al. (2012) Matrix metalloproteinase-9 contributes to the mobilization of bone marrow cells in the injured liver. Cell Transplant 21: 453–464.
25. Chen Y, Xiang LX, Shao JZ, Pan RL, Wang YX, et al. (2010) Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver. J Cell Mol Med 14: 1494–1508.
26. Kollet O, Shvivel S, Chen YQ, Suriswani J, Thung SN, et al. (2003) HGF, SDIF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 112: 160–169.
27. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, et al. (2006) Migration of bone marrow and cord blood hematopoietic stem cells in vitro is regulated by stromal-derived factor-1/CXCR4 and hepatocyte growth factor.
factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24: 1254–1264.

28. Cho KA, Ju SY, Cho SJ, Jung YJ, Woo SY, et al. (2009) Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow. Cell Biol Int 33: 772–777.

29. Kanazawa H, Fujimoto Y, Teratani T, Isawaki J, Kasahara N, et al. (2011) Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One 6: e19195.

30. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, et al. (2004) Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40: 1304–1311.

31. di Bonzo LV, Ferrero I, Cravanzola C, Mareschi K, Rustichelli D, et al. (2008) Human mesenchymal stem cells as a two-edged sword in regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 57: 225–231.

32. Saito Y, Kato H, Nakamura K, Kawanoue Y, et al. (2005) Human mesenchymal stem cells as a two-edged sword in regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 57: 225–231.

33. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, et al. (2001) Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 56: 405–415.

34. Saito Y, Kato H, Nakamura K, Kawanoue Y, et al. (2005) Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106: 756–763.

35. Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, et al. (2009) Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58: 570–581.

36. Sato Y, Araki H, Kato J, Nakamura K, Kawanoue Y, et al. (2005) Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106: 756–763.

37. Aurich I, Mueller LP, Aurich H, Laezkonidou J, Tidjar K, et al. (2007) Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 56: 405–415.

38. Korbing M, Estrov Z (2003) Adult stem cells for tissue repair - a new therapeutic concept. Nat Engl J Med 349: 570–582.

39. Orlic D (2003) Adult bone marrow stem cells regenerate myocardium in ischemic heart disease. Ann N Y Acad Sci 996: 152–157.

40. Fassett J, Toboldt D, Hansen LK (2006) Type I collagen structure regulates cell morphology and EGF signaling in primary rat hepatocytes through cAMP-dependent protein kinase A. Mol Biol Cell 17: 545–556.

41. Trak-Smaya V, Contreras J, Dondoro F, Durand F, Dubois S, et al. (2004) Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation. Transplantation 77: 1753–1760.

42. Majka M, Janosova-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, et al. (2001) Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 97: 3073–3085.

43. Hsao ST, Angari A, Lokmic Z, Sinclair R, Dustin GJ, et al. (2012) Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 21: 2109–2120.

44. Sassoili C, Pini A, Chellini F, Mazzanti B, Nistri S, et al. (2012) Bone marrow mesenchymal stromal cells stimulate skeletal myoblast proliferation through the paracrine release of VEGF. PLoS One 7: e37512.

45. Weil BR, Markel TA, Herrmann JL, Abharbanell AM, Moldrum DR (2009) Mesenchymal stem cells enhance the viability and proliferation of human fetal intestinal epithelial cells following hypoxic injury via paracrine mechanisms. Surgery 146: 190–197.

46. Togel F, Hu Z, Weiss K, Isaac J, Lange C, et al. (2005) Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31–42.

47. Ortiz LA, Dutreil M, Fatman C, Pandey AC, Torres G, et al. (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 104: 11002–11007.

48. Pulavendran S, Vigvsh J, Rose C (2010) Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol 10: 513–519.

49. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, et al. (2004) Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 14: 1035–1041.

50. Serbach C, Henrich D, Trevksbury R, Wilhelm K, Marzi I (2007) Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int 80: 294–300.

51. Ciulla MM, Ferrero S, Gianelli U, Paliosi R, Magrini F, et al. (2007) Direct visualization of neo-vessel formation following peripheral injection of bone marrow derived CD34+ cells in experimental myocardial damage. Micron 38: 321–322.

52. Wang XY, Lan Y, He YW, Zhang L, Yao HY, et al. (2008) Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. Blood 111: 2436–2443.